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ABSTRACT  Gefitinib-related interstitial lung disease (ILD) has been reported as a serious 
adverse effect, associated with a high mortality. Recently, it was reported that gefitinib may 
be effective again following re-administration in cases with a previous history of response to 
gefitinib. However, there have been no reports on the safety of re-administration of gefitinib. We 
report the case of a patient who developed ILD after being restarted on gefitinib, having shown 
complete response, with no serious adverse effects, during/after the first administration. Re-
administration of gefitinib should be considered cautiously, even if the previous administration 
was associated with no side effects.
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IntroDuctIon
   Gefitinib is an orally active inhibitor of EGFR 
tyrosine kinase and is one of the leading EGFR-
targeted agents used in cancer therapy１）. However 
interstitial lung disease (ILD) -type events, 
associated with a high mortality, have been reported 
as serious adverse effects of this agent２）. Recently, 
it was reported that gefitinib may be effective 
again following re-administration in cases with 
a previous history of response to gefitinib３）. 
However, there have been no reports on the safety 
of re-administration of gefitinib. In this report, we 
describe the case of a patient who developed ILD 
after being restarted on gefitinib, having shown 
a good response, without serious adverse effects, 
during/after the first administration.
case report
   A 79-year-old man was admitted our hospital 
because of an abnormal shadow in the right lung 
detected on chest computed tomography (CT). He 
gave a history of smoking one pack of cigarettes 
daily from the age of 30 to 65 years. Transbronchial 
lung biopsy showed adenocarcinoma of the lung. 
Right middle lobectomy was performed, with 
systematic lymph node dissection. Pathological 
examination revealed adenocarcinoma of the mixed 
subtype, and the pathological stage was stage IIIA 
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(T3N2M0). Oral administration of UFT (300 mg/
day) was initiated as adjuvant chemotherapy. 
About 15 months later, the patient presented 
with hemoptysis, and sputum cytology revealed 
adenocarcinoma. CT revealed local recurrence and 
pleural dissemination on the right side (Fig.1A). On 
examination of the surgical specimen, epidermal 
growth factor receptor (EGFR) gene mutation was 
detected. Oral administration of gefitinib (250 
mg/day) was initiated, which led to remarkable 
resolution of the disease. Six months later, no 
abnormal finding was detected on positron emission 
tomography (PET) /CT, and the patient was labeled 
as showing complete response (CR) (Fig.1B). 
About 15 months later, CR, as assessed by PET/
CT, was maintained, however, the patients wished 
to discontinue gefitinib because of generalized 
fatigue and appetite loss. Nine months after 
Fig. 1. Chest computed tomography (CT) scans obtained before (A) and 6 months after 
initiation of treatment with gefitinib (B).
Chest CT scans before reinstitution of gefitinib (C) and after 10 days'  treatment with 
gefitinib (D). CT revealed multiple ground-glass opacities and intralobular septal thickening, 
distributed mainly in the lower and dorsal lung fields bilaterally.
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discontinuation of gefitinib, brain metastasis was 
detected, which was treated by cyber-knife surgery. 
Chest CT revealed relapse of local recurrence in 
the right lung. (Fig.1C) As the patient wished to be 
restarted on gefinitib treatment, oral administration 
of gefitinib (250 mg/day) was initiated. On day 
10 of gefitinib treatment, hypoxia and high fever 
appeared. Thin-slice CT revealed diffuse ground-
glass opacities and intralobular septal thickening, 
distributed mainly in the lower and dorsal lung 
fields bilaterally, and the diagnosis of gefitinib-
related ILD was made. (Fig.1D) Therefore, gefinitib 
was discontinued, and intravenous steroid pulse 
treatment (methylprednisolone 1g/day, 3days) 
was administered. The symptoms and radiological 
findings resolved promptly in response to the steroid 
pulse treatment.
DIscussIon
   Gefitinib-related ILD has been reported as a 
serious adverse effect of gefitinib therapy. In 
a previous study performed by the West Japan 
Thoracic Oncology Group (WJTOG), the incidence 
of gefitinib-induced ILD in Japan was 4% and the 
mortality associated with ILD was 31.6%４）. If this 
adverse effect is excluded, gefitinib has low toxicity. 
   Recently, several cases with re-administration 
of gefit inib have been reported５－８）.  I t  has 
been reported that patients responding to first 
administration may still respond, with survival 
prolongation, to re-administration of the drug. 
To the best of our knowledge, ILD after re-
administration has occurred in two cases until date. 
Inoue et al. described one case of ILD developing 
after treatment was restarted. This patient was 
given gefitinib for 83 days with no serious adverse 
effects; the drug had been discontinued for 1month 
before it was restarted, and the patient developed 
ILD 14 days after it was restarted２）. Suzuki et al. 
described a patient with recurrent gefitinib-related 
ILD. This patient developed ILD 23 days after the 
start of gefitinib treatment, and the ILD recurred 
after gefitinib was restarted９）. Until date, however, 
no information has been collected on the safety of 
re-administration of gefinifib after it is discontinued 
once. In the present case, we thought this patient 
to be gefitinib-induced ILD because he did not 
take other drugs induced ILD. We speculated 
that immunological activation rather than drug 
cytotoxicity might be involved in pathogenesis of 
ILD.
concLusIon
   In this report, we describe the case of a patient 
who developed ILD after being restarted on 
gefitinib, having shown complete response, without 
serious adverse effects, during/after the first 
administration. Thus, re-administration of gefitinib 
should be considered cautiously even if the previous 
administration was associated with no side effects. 
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